Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
Date:10/14/2010

ATLANTA, Oct. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 third quarter financial results will be released on Thursday, November 4, 2010.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available November 4 through November 11 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The account number for the replay is 244 and the conference number is 359197.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  The Company's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  The Company's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  The Company's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  In late September, CryoLife entered into a distribution agreement for PerClot®, an absorbable powder hemostat that has CE Mark designation allowing commercial distribution into the European Community.  CryoLife currently distributes HemoStase®, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in many international markets for cardiac, vascular, and general surgery, subject to certain exclusions, although CryoLife has received notice from Medafor, Inc. that it has terminated its HemoStase distribution agreement with CryoLife.  

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.Media Contact:D. Ashley LeeExecutive Vice President, Chief Financial Officer andChief Operating OfficerPhone: 770-419-3355
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... ... Data integration has been a pharma industry buzzword for the last few ... staff are still working in silos and are not aware of all the data ... more, and nearly one-third of qualified investigators may be overlooked. Innovations in data mapping ...
(Date:12/2/2019)... ... December 02, 2019 , ... Strong public health departments engaged ... and play. Striving to fulfill their crucial mission, more and more health departments ... the Public Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial ...
(Date:11/30/2019)... (PRWEB) , ... November 29, 2019 , ... ... breast cancer screening, that uses deep learning algorithms to automatically detect potential breast ... Annual Radiological Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 06, 2019 , ... Lasair Aesthetic Health Sponsors Toys for Tots to Give Free Toys to ... Who Bring in Toys During the Holidays , Lasair Aesthetic Health is spreading holiday cheer ... who bring in a toy or toys worth more than 25-dollars, will get FIVE units ...
(Date:12/6/2019)... , ... December 06, 2019 , ... Dr. Scott Howell, ... program, recently published research on the health benefits of coconut oil in the 7 ... and Its Effects on the Cardiometabolic Profile: A Structured Literature Review,” led by Dr. ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... announced the Top 54 RHIT Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... Tex-OE, Opuntia Mesocarp Extract®, provides protection from disruptions to cells and tissue and ... the menace of Jet Lag, is available in a dietary supplement product called ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... UNC Health ... easily find their way around the campuses of UNC Medical Center in Chapel Hill ... two hospitals, parking garages, clinics and more. , The free interactive app, developed by ...
Breaking Medicine News(10 mins):